



A web-based questionnaire to evaluate risk factors to develop cow milk allergy

Meltem Dinleyici¹ · Koray Harmanci² · Didem Arslantas⁵ · Yvan Vandenplas³ · Ener Cagri Dinleyici⁴ 

Received: 14 October 2024 / Revised: 22 January 2025 / Accepted: 27 February 2025 / Published online: 14 March 2025
© The Author(s) 2025

Abstract

Many environmental, genetic, and epigenetic variables are considered to influence the evolution of cow's milk allergy (CMA). The gastro-intestinal microbiota may play a direct role in or inhibit tolerance development. In this study, we planned to evaluate the presence of previously identified risk factors for microbiota composition. This study used a cross-sectional electronic survey in Türkiye, utilizing a national convenience sample of 270 children with CMA, as reported by their caregivers, and 2154 healthy controls. We developed a web-based questionnaire to gather information on pregnancy and maternal-related factors, delivery mode, feeding patterns, antibiotic use, and the presence of pets in the home. The risk factors affecting CMA were maternal age (OR 0.897; 0.862–0.934, $p < 0.01$), presence of maternal allergic disorders (OR 3.070; 1.891–4.983, $p < 0.001$) and in both parents (OR 3.831; 1.202–12.210, $p < 0.001$), maternal weight at conception (OR 1.016; 1.003–1.030, $p < 0.05$), maternal weight gain during pregnancy (OR 1.033; 1.012–1.056, $p < 0.01$), (absence of a) pet at home (OR 1.394; 1.003–1.938, $p < 0.05$), intrapartum antibiotic use (OR 1.469; 1.092–1.975, $p < 0.05$), antibiotic use during the first 6 months of life (OR 1.933; 1.306–2.863, $p < 0.001$), and number of householders (OR 0.794; 0.650–0.969, $p < 0.05$). **Conclusion:** In addition to allergic disorders in parents, maternal weight and weight gain during pregnancy, intrapartum and first 6 months of life antibiotic use, and the presence of pets at home were found to be microbiota-related risk factors in children with CMA. Potential strategies related to microbiota composition may contribute positively to the disease's development and progression.

What Is Known:

- The gut microbiome contributes to the development of cow milk allergy, and disrupted microbiota maturation during the first year of life appears to be common in pediatric food allergies.
- Factors that influence an infant's microbiota within the first 1000 days and the relationship between these factors and microbiota may enhance allergy diagnosis, prevention, and treatment.

What Is New:

- Besides parental allergy disorders, maternal weight and weight gain during pregnancy, antibiotic use during intrapartum and first six months of life, and the presence of pets at home were identified as microbiota-related risk factors in children with CMA.

Keywords Cow's milk allergy · Food allergy · Microbiota · Antibiotic · Microbiome

Communicated by Tobias Tenenbaum

✉ Ener Cagri Dinleyici
timboothtr@yahoo.com

¹ Department of Social Pediatrics, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey

² Department of Pediatric Allergy Immunology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey

³ Vrije Universiteit Brussel, UZ Brussels, KidZ Health Castle, Brussels, Belgium

⁴ Department of Pediatrics, Faculty of Medicine, Eskisehir Osmangazi University, TR-26040 Eskisehir, Turkey

⁵ Department of Public Health, Eskisehir Osmangazi University, Eskisehir, Turkey

Abbreviations

CMA Cow milk allergy
OR Odds ratio

Introduction

The rise in non-communicable diseases, including allergic diseases, in recent years has become worldwide an important health burden [1]. Cow's milk allergy (CMA) is the predominant food allergy in infancy, with a prevalence ranging from 0.54 to 4.9%, contingent upon geographic location and feeding method (human milk versus formula feeding) [2]. Recent studies suggest that the gut microbiome plays a role in the development of allergic diseases, including CMA [3–5]. Advancements in microbiome research over the past two decades have revealed a potential correlation between the establishment of the microbiome during the first 1000 days of life and the onset of various non-communicable diseases [4, 6]. While evidence continues to affirm that microbe-host interactions govern immune regulation, recent data indicates that interactions with both environmental microorganisms and the human microbiota are crucial in modifying this process [7]. The microbiota can, under specific circumstances, directly contribute to the failure of tolerance development, resulting in food allergy sensitivity and dysbiosis. Conversely, it can promote the (re-)establishment of tolerance at other periods [4, 8, 9]. The composition of the infant microbiome is dynamic and strongly influenced by maternal, infant, and environmental-related factors. For breastfed infants, the mother is the most influential factor in the composition of the infant's microbiota throughout the first 1000 days of life. Aside from the mother's intestinal microbiota, the composition of mother's milk and its microbial content also contribute [6, 10–13]. Antibiotics administered to the mother and/or the infant can also disrupt gut homeostasis and significantly raise the risk of allergic diseases [4, 14, 15].

Disruption of the integrity and function of the epithelial barrier is a consequence of dysbiosis [16]. Research indicates that the microbiota significantly contributes to maintaining the integrity of the mucosal epithelial barrier, which in turn plays a crucial role in immune system regulation, dysregulation, and the development of allergies. Infants with CMA exhibit variations in symptoms, disease progression, and in the acquisition of tolerance [17]. Many environmental, genetic, and epigenetic variables are considered to influence the evolution of CMA [18, 19]. Hoskinson and colleagues [20] looked at early-life factors and microbiome features in 1115 children who were part of the CHILD study birth cohort. At age 5, these factors consistently linked to four different allergic diagnoses: atopic dermatitis, asthma, food allergies, and allergic rhinitis. They collected extensive data, including familial demographic data, mode of delivery,

birth weight, breastfeeding, antibiotic use, and detailed allergy evaluation. They showed that impaired first-year microbiota maturation seems universal to pediatric allergies, including food allergies. They showed a decrease in gut microbiome maturation, within the alteration of a core group of species, functional pathways, and metabolic imbalance associated with reduced microbiota-maturation age and elevated risk of allergy. They highlighted that microbiota maturation during the early period of life provides a focal point to identify deviations from normative development to predict and prevent allergic disease [20]. Better understanding of the factors that influence an infant's microbiota during the first 1000 days and the correlation between these factors and microbiota disorders could improve allergy diagnosis, prevention, and treatment. Currently, there is no effective treatment available for FA, with avoidance being the primary measure [17]. In this study, we planned to evaluate the presence of previously identified risk factors for dysbiosis in children with CMA and compare them to healthy children.

Methods

The microbalance study is a project evaluating microbiota composition and associated factors in healthy and fault children. In this part, we developed a self-completion web-based questionnaire for parents with the intention to determine risk factors related to microbiota composition in their children. We created a web-based questionnaire via SurveyMonkey, which included 70 questions relevant to previously described microbiota-related risk factors, including maternal factors during pregnancy, delivery mode, breastfeeding, and complementary feedings. Parents who have a child with physician-diagnosed CMA responded to 30 additional questions about CMA symptoms, signs, and follow-up. We sent an electronic cover letter and questionnaire via SurveyMonkey to a convenience sample of participants, which included parents of both children with CMA and healthy children. We mailed the questionnaire along with a cover letter that outlined the study details, emphasized its purpose and confidentiality, and reminded potential participants that their participation was voluntary. The study did not provide any financial incentives for participation. The Eskisehir Osmangazi University Faculty of Medicine Local Ethical Committee (01.06.2021/08) approved this study. The procedures conducted in this trial adhered to the ethical criteria set by the institutional and/or national research committee, as well as the 1964 Helsinki Declaration and its subsequent revisions or similar ethical standards. All participants confirmed their agreement to participate in the study before responding to the online questionnaire.

Inclusion and exclusion criteria

Parents (mother or father) who have children with physician-confirmed CMA or healthy children between 6 and 120 months and agreed to participate in this study. For healthy children, the exclusion criteria include the presence of chronic disease, chronic medication, and relevant surgical interventions. We exclude questionnaires not properly filled out.

Questionnaire

The questionnaire encompassed questions related to the following topics: demographic variables of the child, such as age, gender, and city of residence; and parental demographic variables, such as age, educational status, number of children, and allergic disorders. The questionnaire also inquired about the house and living conditions, including the presence of a garden, the number of rooms, the number of householders, smoking status, and the presence of pets such as cats and dogs, during pregnancy and beyond. We also collected information on maternal diseases like gestational diabetes, hypertension, urinary tract infections, the use of antibiotics during pregnancy, the mother's weight and height at conception, her weight at delivery, and the absolute and percentage weight gain during pregnancy. Other factors include delivery mode (vaginal or C-section), the type of C-section (emergency or elective), and the use of antibiotics intrapartum or during the first 7 days after delivery; gestational age, birth weight, and antibiotic use during the first 1 month and 6 months of life; exclusive breastfeeding during the first 6 months of life; formula feeding; probiotic use; and the reason for probiotic use.

CMA-related questions

If the parents answered affirmatively to the question “Does your child have an allergy to cow’s milk, and has this diagnosis been confirmed by a physician?” they are asked to answer additional questions regarding the symptoms, signs, and follow-up of CMA. This section of the questionnaire contains questions regarding the symptoms associated with CMA, such as vomiting, diarrhea, presence of blood or mucus in stool, constipation, skin abnormalities (including eczema), respiratory system symptoms, anaphylaxis or angioedema, anal lesions, failure to gain weight, and colic or abdominal pain. It also includes inquiries about the presence of other concurrent conditions, such as infantile colic, atopic dermatitis, allergic rhinitis, asthma, celiac disease, frequent infections (more than 8 per year), and constipation. Information is also collected regarding nebulization treatment, a specific CMA formula, and if an epinephrine autoinjector was prescribed.

Statistical analysis

We sent 3200 questionnaires via SurveyMonkey for this study. In 2601 of these questionnaires, the responses were adequate to perform further analysis. Parents of healthy children completed 2154 of these questionnaires. 447 parents reported that their child had a “food allergy”. After evaluating 447 questionnaires, we found that 270 of them had an only cow’s milk allergy, which we then included in the analysis. We excluded 177 questionnaires due to non-cow’s milk food allergies or multiple food allergies. In total, 2601 parents responded to the questionnaire. We conducted the final analyses on 270 children diagnosed with CMA and 2154 children presumed to be healthy. We used the SPSS Statistical Package for the Social Sciences (Illinois, CA, USA) for the statistical analysis. We depicted the quantitative variables using the mean value plus or minus the standard deviation for normally distributed data, or the median with the interquartile range for non-normally distributed data. We used independent *t*-tests to compare continuous data according to a normal distribution and applied Mann–Whitney *U* tests for data that deviated from normality. We evaluated the associations among qualitative factors with a chi-square test. We computed the odds ratios (OR) for the CMA group, utilizing the healthy group as the reference cohort. We also used stepwise logistic regression and a likelihood ratio test to build a model and examine CMA risk factors. We considered a *p*-value less than 0.05 as statistically significant.

Results

This study included 270 children diagnosed with CMA. Signs of CMA that were present at diagnosis were vomiting in 74 cases (27.4%), diarrhea (*n*:76; 28.1%), blood or mucus in the stool (*n*: 152; 56.3%), constipation (*n*:24; 8.9%), skin problems (including eczema) (*n*: 168; 62.2%), respiratory symptoms including wheezing (*n*:46; 17%), anaphylaxis or angioedema (*n*: 5; 1.9%), anal lesions (*n*: 7; 2.6%), faltering growth (*n*: 4; 1.5%), infantile colic (*n*:73, 27%) and 12 (4.4%) had frequent infections. The majority of the mothers (*n*:206; 76.3%) adhered to a dietary regimen. 45 patients, or 16.7% of the total, received prescriptions for Epinephrine autoinjectors were prescribed for 45 children (16.7% of the total).

Comparison of microbiota-related risk factors between children with CMA and healthy children

A comparison of the microbiota-related traits of the 270 children CMA (151 boys and 110 girls) with those of the 2154 healthy children (1125 boys and 1029 girls) is shown in Table 1. There is no statistically significant difference

Table 1 Comparison of demographical and presence of microbiota-related risk factors between children with CMA and healthy children

	CMA (<i>n</i> =270)	Healthy children (<i>n</i> =2154)	OR 95%CI; <i>p</i>
Age (months)	39.4 ± 31.9	41.8 ± 32.2	ns
Gender (boys/Girls)	151/119	1125/1029	ns
Mother age (years)	34.7 ± 6.1	39.7 ± 5.9	<i>p</i> < 0.001
Father age (years)	37.7 ± 6.4	42.4 ± 6.6	<i>p</i> < 0.001
Presence of allergic disorders			
Mother <i>n</i> (%)	45 (16.7)	100 (4.6)	OR 4.105 95%CI 2.746–6.065; <i>p</i> < 0.001
Father <i>n</i> (%)	18 (6.7)	45 (2.1)	OR 3.345 95%CI 1.794–6.004; <i>p</i> < 0.001
Both parents <i>n</i> (%)	11 (4.1)	7 (0.3)	OR 12.999 95%CI 4.556–39.903; <i>p</i> < 0.001
Number of children at home	1.37 ± 0.5	1.54 ± 0.6	<i>p</i> < 0.001
Number of household members	2.35 ± 0.7	2.57 ± 0.7	<i>p</i> < 0.001
Number of rooms	3.56 ± 0.7	3.67 ± 0.8	<i>p</i> < 0.05
Presence of garden	171 (63.3)	1593 (74.0)	OR 0.607 95%CI 0.462–0.801; <i>p</i> < 0.001
Mother smoking status	58 (21.5)	547 (25.4)	ns
Father smoking status	107 (39.6)	722 (33.5)	OR 1.302 95%CI 0.994–1.700; <i>p</i> < 0.05
Smoking status at home	144 (53.3)	1162 (53.9)	ns
Presence of pet during pregnancy			
Cat	16 (5.9)	120 (5.6)	ns
Dog	10 (3.7)	55 (2.6)	ns
Bird	10 (3.7)	80 (3.7)	ns
None	234 (86.7%)	1899 (88.1%)	ns
Presence of pet after pregnancy			
Cat	23 (8.5)	340 (15.8)	OR 0.497 95%CI 0.304–0.777; <i>p</i> < 0.01
Dog	10 (3.7)	141 (6.5)	ns
Bird	18 (6.7)	224 (10.4)	ns
None	219 (81.1%)	1449 (67.2%)	OR 1.897 95%CI 1.407–2.582; <i>p</i> < 0.001
Disorders during pregnancy			
Gestational diabetes	23 (8.5)	164 (7.6)	ns
Hypertension	8 (3.0)	65 (3.0)	ns
Urinary tract infections	43 (15.9)	147 (6.8)	OR 2.585 95%CI 1.747–3.765; <i>p</i> < 0.001
Antibiotic usage during pregnancy	49 (18.1)	183 (8.5)	OR 2.387 95%CI 1.654–3.399; <i>p</i> < 0.001
At first day of pregnancy			
Maternal weight (kg)	62.4 ± 10.8	60.9 ± 10.3	<i>p</i> < 0.05
Maternal BMI (kg/m ²)	23.0 ± 3.9	22.5 ± 3.69	ns
Overweight	47 (17.9)	312 (14.9)	ns
Obesity	16 (6.1)	102 (4.9)	ns
Maternal diet preference			
None	241 (89.2)	1846 (85.7)	ns
Gluten free	6 (2.2)	40 (1.9)	ns
Intermittent fasting	14 (5.2)	137 (6.4)	ns
Vegan/vegetarian	9 (3.3)	29 (1.3)	ns
Weight gain (kg) during pregnancy	15.5 ± 6.32	14.6 ± 6.61	<i>p</i> < 0.01
Weight gain (%) during pregnancy	25.8 ± 11.3	24.9 ± 12.0	<i>p</i> < 0.05
Maternal weight at labor	77.9 ± 11.3	75.4 ± 11.2	< 0.001

Table 1 (continued)

	CMA (<i>n</i> = 270)	Healthy children (<i>n</i> = 2154)	OR 95%CI; <i>p</i>
Delivery mode			
Vaginal delivery	61 (22.6)	484 (22.4)	ns
C-section	209 (77.4)	1670 (77.5)	ns
Emergency C-section	80 (29.6)	546 (25.3)	ns
Elective C-section	129 (47.8)	1124 (52.2)	ns
Intrapartum or first 7 days antibiotic use	113 (41.9)	590 (27.4)	OR 1.904 95%CI 1.454–2.487; <i>p</i> < 0.001
Birth weight (gram)	3357 ± 541	3250 ± 562	<i>p</i> < 0.01
Prematurity	51 (18.9)	517 (24.0)	ns
Breastfeeding during first 24 h of life	242 (89.6)	1924 (89.3)	ns
Exclusive breastfeeding during first 6 months of life	110 (40.7)	898 (41.7)	ns
Formula feeding	160 (59.3)	1256 (58.3)	ns
Formula feeding at first months of life	96 (35.6)	657 (30.5)	ns
Formula feeding at first 4 months of life	129 (47.7)	983 (45.6)	ns
Formula feeding at 6 months of life	158 (58.5)	1202 (55.8)	ns
Antibiotic use at first month of life	103 (39.0)	393 (19.2)	OR 2.681 95%CI 2.023–3.543; <i>p</i> < 0.001
Antibiotic use at first 6 months of life	151 (57.2)	653 (31.9)	OR 2.839 95%CI 2.170–3.722; <i>p</i> < 0.001

in age and gender distribution ($p > 0.05$) of the children. The maternal and paternal age of children were lower in the CMA group than in the control group ($p < 0.001$ for both). The prevalence of allergic disorders was significantly greater among both parents in the group with CMA compared to the group of healthy children ($p < 0.001$ for all). The number of children and household members at home was lower in the CMA group ($p < 0.001$ for both). The proportion of children residing in an apartment was greater in the CMA group compared to the healthy children ($p < 0.05$). The number of rooms and the percentage of a garden at home were both lower in the CMA group. The father's smoking status is significantly greater in children with CMA compared to healthy children ($p < 0.05$). Throughout pregnancy, the prevalence of pets such as cats, dogs, or birds was comparable across all groups. The presence of pets, specifically cats, at home after pregnancy was higher in the CMA group compared to the control group ($p = 0.001$).

During pregnancy, there was no significant difference in the occurrence of gestational diabetes and hypertension across the groups ($p > 0.05$). Nevertheless, urinary tract infections and the use of antibiotics for any reason during pregnancy were more prevalent in children with CMA compared to healthy children ($p < 0.001$).

Maternal weight was significantly higher in mothers of children with CMA compared to mothers of healthy children at the beginning of pregnancy ($p = 0.036$). The maternal BMI and maternal overweight/obesity status did not differ significantly across the groups ($p > 0.05$). The average weight gain during pregnancy, the percentage of weight

gain during pregnancy, and the final weight of mothers at the time of labor were all higher in mothers of children with CMA compared to mothers of healthy children (with p -values of < 0.032 , < 0.033 , and < 0.001 , respectively). The rates of vaginal delivery, or C-section, were similar between the two groups. Between the groups, the rates of emergency C-section and elective C-section were comparable, with no statistically significant difference ($p > 0.05$).

Healthy infants had a higher incidence of prematurity ($p = 0.034$), and children with CMA had significantly higher birth weights compared to healthy children ($p = 0.03$). The use of antibiotics during labor and delivery, as well as during the first week after giving birth, was considerably greater in the group of mothers with a history of chronic medical conditions compared to the group of healthy mothers ($p < 0.001$). The use of antibiotics during the first months of infancy, as well as the first 6 months of life, is more common in children with CMA compared to healthy children ($p = 0.0024$ and $p = 0.0001$, respectively). The rates of breastfeeding initiation during the first 24 h of birth and exclusive breastfeeding for the first 6 months of life were comparable among the groups. The rates of formula feeding during the initial months of life, specifically the first 4 and 6 months, did not differ significantly across the groups ($p > 0.05$).

Logistic regression analysis was performed in the model created with the variables of mother's and father's age, presence of maternal allergic disorders, presence of allergic disorders in both parents, maternal urinary tract infections during pregnancy and antibiotic use, maternal weight at

conception, intrapartum antibiotic use, antibiotic use during the first and first six months of life, presence of a pet at home, and number of householders to determine the factors affecting CMA risk. The risk factors affecting CMA were maternal age (OR 0.897; 0.862–0.934, $p < 0.01$), presence of maternal allergic disorders (OR 3.070; 1.891–4.983, $p < 0.001$), presence of allergic disorders in both parents (OR 3.831; 1.202–12.210, $p < 0.001$), maternal weight at conception (OR 1.016; 1.003–1.030, $p < 0.05$), maternal weight gain during pregnancy (OR 1.033; 1.012–1.056, $p < 0.01$), no pet at home (OR 1.394; 1.003–1.938, $p < 0.05$), intrapartum antibiotic use (OR 1.469; 1.092–1.975, $p < 0.05$), antibiotic use during the first 6 months of life (OR 1.933; 1.306–2.863, $p < 0.001$), and number of householders (OR 0.794; 0.650–0.969, $p < 0.05$).

Discussion

This study revealed a correlation between infants with CMA and factors such as maternal age, the presence of allergic disorders in the mother or in both parents, maternal weight at conception, and weight gain during pregnancy. Also, administration of antibiotics during intrapartum or during the first 6 months of life was found to be related factors. The number of householders and the presence of pets at home also played a significant role.

Studies that looked at the relationship between changes in the microbiota's diversity and/or function and becoming sensitive to foods early in life suggest that the microbiome may be an interfering factor with the development of food allergies, such as CMA [4, 21]. A plethora of modifiable risk factors has been identified that elevate an individual's susceptibility to food allergies, including delivery mode, baby feeding practices, maternal nutrition, antibiotic use during gestation, and rural versus urban residency [17, 22]. Contemporary research indicates that it is probably a confluence of risk factors. Both controllable and nonmodifiable risk factors affect the composition of an individual's gut microbiota [23].

While exposure to microbes likely occurs already during pregnancy, the infant's microbiota composition is undoubtedly influenced by maternal and pregnancy-related factors at birth [6]. Researchers have reported that excessive gestational weight gain increases the risk of childhood allergic diseases, especially asthma [24]. Our data regarding the weight of the mother endorses this hypothesis. While there are conflicting results regarding the relationship between gestational weight gain and food allergies, our study suggests that maternal weight gain appears to be related to CMA. A notable connection between maternal diet during gestation or breastfeeding and reduced risk of later allergy illness in the child was better adherence to a Mediterranean diet.

Conversely, studies often, but not uniformly, indicate that a maternal diet during gestation rich in vegetable oils, margarine, nuts, and fast food elevates a child's risk of having allergic disease [17, 25]. Research about food allergies indicates that incorporating common allergens into the maternal diet during gestation and lactation may provide protective benefits, but some trials yielded ambiguous results [17].

Children with CMA have a higher frequency of infection and use of antibiotics compared to healthy children [26]. In our study, intrapartum antibiotic use is 1.4 times higher, and antibiotic use during the first 6 months of life is 1.9 times higher in children with CMA than in the healthy group. Exposure to antibiotics during pregnancy can increase the risk for children to develop allergic disorders [27]. Both prenatal and postnatal antibiotic exposure have been linked to a heightened risk of asthma [27]. Antibiotics can modify the composition of the native microbial population, thus diminishing their variety and impacting their genetic traits and functionality [4, 27]. Regrettably, the use of intrapartum antibiotics is escalating in conjunction with the rising frequency of cesarean section deliveries [27, 28]. However, our study failed to demonstrate the association between allergic diseases and cesarean sections. Our study cohort also confirmed the high rates of cesarean sections in Türkiye [29]. Although cesarean sections did not seem to be effective, intrapartum antibiotic use was associated with them, suggesting the effect of this factor on the development of CMA. Most infants receive multiple courses of antibiotics during the first two years of life [30]. Research from human studies associates the utilization of antimicrobial drugs with a rise in food allergy prevalence, particularly during the newborn period, which is a crucial time for antibiotic exposure [4]. Love et al. demonstrated a significant increase in the likelihood to develop food allergy in children who received five or more antibiotic prescriptions in their first year of life [31]. In these cases, interventions aimed at reducing antibiotic use may have positive effects on the development of allergic disorders. Therefore, rational antibiotic use may have positive effects on the microbiota composition and may lead to changes in the disease's development and course.

Our study had some limitations. The study utilized a questionnaire that gathered information from the parents. The study included physician-diagnosed CMA cases, but the patient information was based on parental evaluations rather than on the medical records. For this reason our analysis does not include data on allergic sensitization including results from prick tests or specific IgE levels. In this study, we did not perform microbiota analysis, this is a questionnaire study about the risk factors. This is a retrospective part of the our microbalance study. We planned to perform a prospective study with these risk factors and microbiota analysis together. The study's strength was that we reached a sufficient number of patients in the CMA and control groups,

as well as patients from all regions of the country and different sociocultural levels.

Prior research indicates that early infancy, particularly between 3 and 6 months of age, is a critical period during which gut microbiota influences the development of food allergies [17]. Nonetheless, it remains uncertain whether sustaining this “healthy” gut flora is sufficient to elicit tolerance to food [4]. While recent discussions have highlighted the beneficial effects of environmental regulation on microbiota restoration, our study revealed that genetic factors play a more significant role in the development of allergic disease in mothers and parents. These factors cannot be changed. Therefore, controlling other associated microbiota-related factors in children with a family history of allergy may be beneficial.

Acknowledgements We thank all participants and parents in this study.

Authors’ contributions M.D., K.H. and E.C.D. conceptualized and designed the study, D.A performed the analysis, D.A and E.C.D. interpreted the analyses, M.D and Y.V prepared the first draft. All authors have read and agreed to the published version of the manuscript.

Funding Open access funding provided by the Scientific and Technological Research Council of Türkiye (TÜBİTAK).

Data availability The data are available from the corresponding author upon reasonable request.

Declarations

Ethics approval This study was approved by the Eskisehir Osmangazi University Faculty of Medicine Local Ethical Committee (01.06.2021/08). The procedures conducted in this trial adhered to the ethical criteria set by the institutional and/or national research committee, as well as the 1964 Helsinki Declaration and its subsequent revisions or similar ethical standards.

Informed consent All participants engaged in the study provided informed consent before fulfilling the questionnaire.

Competing interests ECD has participated as a clinical investigator, advisory board member, consultant, and speaker for BioGaia, Biocodex, Nestle Health Science, Nestle Nutrition Institute and Nutricia. KH has participated as an advisory board member, consultant, and speaker for Nutricia. YV participated as a clinical investigator, and/or advisory board member, and/or consultant, and/or speaker for Abbott Nutrition, Alba Health, Arla, Biogaia, Danone, ELSE Nutrition, Friesland Campina, Nestle Health Science, Nestle Nutrition Institute, Nutricia, Pileje, United Pharmaceuticals (Novalac). The other authors declare no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not

permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. -Noncommunicable diseases. <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>. Last Access date 05 Oct 2024
2. Vandenplas Y, Brough HA, Fiocchi A, Miqdady M, Munasir Z, Salvatore S, Thapar N, Venter C, Vieira MC, Meyer R (2021) Current guidelines and future strategies for the management of cow’s milk allergy. *J Asthma Allergy* 21(14):1243–1256. <https://doi.org/10.2147/JAA.S276992>
3. Ptaschinski C, Gibbs BF (2024) Early-life risk factors which govern pro-allergic immunity. *Semin Immunopathol* 46(3–4):9. <https://doi.org/10.1007/s00281-024-01020-x>
4. Shu SA, Yuen AWT, Woo E, Chu KH, Kwan HS, Yang GX, Yang Y, Leung PSC (2019) Microbiota and food allergy. *Clin Rev Allergy Immunol* 57(1):83–97. <https://doi.org/10.1007/s12016-018-8723-y>
5. Moriki D, Francino MP, Koumpagioti D, Boutopoulou B, Rufián-Henares JÁ, Priftis KN, Dourous K (2022) The role of the gut microbiome in cow’s milk allergy: a clinical approach. *Nutrients* 14(21):4537. <https://doi.org/10.3390/nu14214537>
6. Pantazi AC, Balasa AL, Mihai CM, Chisnoiu T, Lupu VV, Kasim MAK, Mihai L, Frecus CE, Chirila SI, Lupu A, Andrusca A, Ionescu C, Cuzic V, Cambrea SC (2023) Development of gut microbiota in the first 1000 days after birth and potential interventions. *Nutrients* 15(16):3647. <https://doi.org/10.3390/nu15163647>
7. Zheng D, Liwinski T, Elinav E (2020) Interaction between microbiota and immunity in health and disease. *Cell Res* 30(6):492–506. <https://doi.org/10.1038/s41422-020-0332-7>
8. Liang J, Zheng B, Zhang Y, Zeng H (2023) Food allergy and gut microbiota. *Trends Food Sci Technol* 140:104141
9. Poto R, Fusco W, Rinninella E, Cintoni M, Kaitsas F, Raoul P, Caruso C, Mele MC, Varricchi G, Gasbarrini A, Cammarota G, Ianiro G (2023) The role of gut microbiota and leaky gut in the pathogenesis of food allergy. *Nutrients* 16(1):92. <https://doi.org/10.3390/nu16010092>
10. Stewart CJ, Ajami NJ, O’Brien JL, Hutchinson DS, Smith DP, Wong MC, Ross MC, Lloyd RE, Doddapaneni H, Metcalf GA, Muzny D, Gibbs RA, Vatanen T, Huttenhower C, Xavier RJ, Rewers M, Hagopian W, Toppari J, Ziegler AG, She JX, Akolkar B, Lernmark A, Hyoty H, Vehik K, Krischer JP, Petrosino JF (2018) Temporal development of the gut microbiome in early childhood from the TEDDY study. *Nature* 562(7728):583–588. <https://doi.org/10.1038/s41586-018-0617-x>
11. Notarbartolo V, Carta M, Accomando S, Giuffrè M (2023) The first 1000 days of life: how changes in the microbiota can influence food allergy onset in children. *Nutrients* 15(18):4014. <https://doi.org/10.3390/nu15184014>
12. Davis EC, Monaco CL, Insel R, Järvinen KM (2024) Gut microbiome in the first 1000 days and risk for childhood food allergy. *Ann Allergy Asthma Immunol* 133(3):252–261. <https://doi.org/10.1016/j.anai.2024.03.010>
13. Biagioli V, Volpedo G, Riva A, Mainardi P, Striano P (2024) From birth to weaning: a window of opportunity for microbiota. *Nutrients* 16(2):272. <https://doi.org/10.3390/nu16020272>
14. Kim H, Sitarik AR, Woodcroft K, Johnson CC, Zoratti E (2019) Birth mode, breastfeeding, pet exposure, and antibiotic use: associations with the gut microbiome and sensitization in children.

- Curr Allergy Asthma Rep 19(4):22. <https://doi.org/10.1007/s11882-019-0851-9>
15. Pettersen VK, Arrieta MC (2020) Host-microbiome intestinal interactions during early life: considerations for atopy and asthma development. *Curr Opin Allergy Clin Immunol* 20(2):138–148. <https://doi.org/10.1097/ACI.0000000000000629>
 16. Celebi Sözen Z, Cevhertas L, Nadeau K, Akdis M, Akdis CA (2020) Environmental factors in epithelial barrier dysfunction. *J Allergy Clin Immunol* 145(6):1517–1528. <https://doi.org/10.1016/j.jaci.2020.04.024>
 17. Jungles KN, Jungles KM, Greenfield L, Mahdavinia M (2021) The infant microbiome and its impact on development of food allergy. *Immunol Allergy Clin North Am* 41(2):285–299. <https://doi.org/10.1016/j.iac.2021.01.004>
 18. Robert E, Al-Hashmi HA, Al-Mehaidib A, Alsarrar K, Al-Turaiki M, Aldekhail W, Al-Herz W, Alkhabaz A, Bawakid KO, Elghoudi A, El Hodhod M, Hussain AA, Kamal NM, Goronfolah LT, Nasrallah B, Sengupta K, Broekaert I, Domellöf M, Indrio F, Lapillonne A, Pienar C, Ribes-Koninckx C, Shamir R, Szajewska H, Thapar N, Thomassen RA, Verduci E, West CE, Vandenplas Y (2024) Symptoms and management of cow's milk allergy: perception and evidence. *Front Allergy* 13(5):1348769. <https://doi.org/10.3389/falgy.2024.1348769>
 19. Vandenplas Y, Broekaert I, Domellöf M, Indrio F, Lapillonne A, Pienar C, Ribes-Koninckx C, Shamir R, Szajewska H, Thapar N, Thomassen RA, Verduci E, West C (2024) An ESPGHAN position paper on the diagnosis, management, and prevention of cow's milk allergy. *J Pediatr Gastroenterol Nutr* 78(2):386–413. <https://doi.org/10.1097/MPG.0000000000003897>
 20. Hoskinson C, Dai DLY, Del Bel KL, Becker AB, Moraes TJ, Mandhane PJ, Finlay BB, Simons E, Kozyskyj AL, Azad MB, Subbarao P, Petersen C, Turvey SE (2023) Delayed gut microbiota maturation in the first year of life is a hallmark of pediatric allergic disease. *Nat Commun* 14(1):4785. <https://doi.org/10.1038/s41467-023-40336-4>
 21. Iweala OI, Nagler CR (2019) The microbiome and food allergy. *Annu Rev Immunol* 26(37):377–403. <https://doi.org/10.1146/annurev-immunol-042718-041621>
 22. Tuniyazi M, Li S, Hu X, Fu Y, Zhang N (2022) The role of early life microbiota composition in the development of allergic diseases. *Microorganisms* 10(6):1190. <https://doi.org/10.3390/microorganisms10061190>
 23. Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J, Chen ZS (2022) Microbiota in health and diseases. *Signal Transduct Target Ther* 7(1):135. <https://doi.org/10.1038/s41392-022-00974-4>
 24. Ojwang V, Nwaru BI, Hanna-Mari T, Heli T, Kaila M, Ahonen S, Niemelä O, Haapala AM, Ilonen J, Toppari J, Hyöty H, Veijola R, Knip M, Virtanen SM (2024) Early-pregnancy BMI, maternal gestational weight gain, and asthma and allergic diseases in children. *Pediatr Allergy Immunol* 35(9):e14240. <https://doi.org/10.1111/pai.14240>
 25. Venter C, Agostoni C, Arshad SH, Ben-Abdallah M, Du Toit G, Fleischer DM, Greenhawt M, Glueck DH, Groetch M, Lunjani N, Maslin K, Maiorella A, Meyer R, Antonella M, Netting MJ, Ibeabughichi Nwaru B, Palmer DJ, Palumbo MP, Roberts G, Roduit C, Smith P, Untersmayr E, Vanderlinden LA, O'Mahony L (2020) Dietary factors during pregnancy and atopic outcomes in childhood: a systematic review from the European Academy of Allergy and Clinical Immunology. *Pediatr Allergy Immunol* 31(8):889–912. <https://doi.org/10.1111/pai.13303>
 26. Fiochi A, Knol J, Koletzko S, O'Mahony L, Papadopoulos NG, Salminen S, Szajewska H, Nowak-Węgrzyn A (2021) Early-life respiratory infections in infants with cow's milk allergy: an expert opinion on the available evidence and recommendations for future research. *Nutrients* 13(11):3795. <https://doi.org/10.3390/nu13113795>
 27. Metsälä J, Lundqvist A, Virta LJ, Kaila M, Gissler M, Virtanen SM (2015) Prenatal and post-natal exposure to antibiotics and risk of asthma in childhood. *Clin Exp Allergy* 45(1):137–145. <https://doi.org/10.1111/cea.12356>
 28. Moore J, Navarro S, McCarthy K, Rashid RB, Phipps S, Amoako A, Callaway L, Eley V (2023) State of the art: Intrapartum antibiotics in cesarean section, the infant microbiota and allergic diseases. *Acta Obstet Gynecol Scand* 102(7):811–820. <https://doi.org/10.1111/aogs.14577>
 29. Ulgu MM, Birinci S, Altun Ensari T, Gözükar MG (2023) Cesarean section rates in Turkey 2018–2023: Overview of national data by using Robson ten group classification system. *Turk J Obstet Gynecol* 20(3):191–198. <https://doi.org/10.4274/tjod.galenos.2023.68235>
 30. - Duong QA, Pittet LF, Curtis N, Zimmermann P (2022) Antibiotic exposure and adverse long-term health outcomes in children: a systematic review and meta-analysis. *J Infect* 85(3):213–300. <https://doi.org/10.1016/j.jinf.2022.01.005>. Epub 2022 Jan 10. Erratum in: *J Infect*. 2023 Jan;86(1):118. <https://doi.org/10.1016/j.jinf.2022.10.035>
 31. Love BL, Mann JR, Hardin JW, Lu ZK, Cox C, Amrol DJ (2016) Antibiotic prescription and food allergy in young children. *Allergy Asthma Clin Immunol* 17(12):41. <https://doi.org/10.1186/s13223-016-0148-7>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.